Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.
We have investigated the hypothesis that carcinoma of the prostate with skeletal metastases is associated with increased bone resorption. In 54 affected patients a close correlation was observed between serum activity of alkaline phosphatase and urinary excretion of hydroxyproline (r = +0.818; P less than 0.001), comparable to that seen in Paget's disease of bone. The administration of synthetic salmon calcitonin (100 U subcutaneously) induced a significant fall in serum calcium and urinary excretion of hydroxyproline, proportional to the prevailing rate of bone turnover, as assessed by serum alkaline phosphatase or hydroxyprolinuria. Administration of the diphosphonate, etidronate, also decreased hydroxyprolinuria, suggesting that urinary hydroxyproline reflected increased rates of bone resorption in this disorder. Histology of bone in sites adjacent to and distant from skeletal metastases showed increased histological indices of bone resorption. These results suggest that the skeletal disease associated with prostatic carcinoma is characterized by generalized increases in bone resorption as well as focal increases in bone formation.
D000368:Aged; D001706:Biopsy; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D001862:Bone Resorption / Q000378:metabolism* / Q000473:pathology; D002116:Calcitonin; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D012968:Etidronic Acid; D006801:Humans; D007085:Ilium / Q000473:pathology; D008297:Male; D010001:Osteitis Deformans / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology
D002116:Calcitonin; D012968:Etidronic Acid